The white paper, or policy document, outlines the strategic vision of NCHHSTP for reducing health disparities and promoting health equity among populations affected by these diseases. NCHHSTP is committed to promoting awareness, stakeholder and community engagement, and action on factors that can affect the nation and the world's health; to addressing these factors in the policy, practice, and research activities of NCHHSTP; and to building partnerships on every level.
Favorite
Asian or Pacific Islander persons
Non-U.S.-born persons
Hispanic or Latino persons
American Indian or Alaska Native persons
Policy Makers
2010
Delivering HIV Rapid Test Results: Experiences from the Field is a short (approximately 30 minute) video that combines real stories from providers delivering rapid test results and clients learning their test results, as well as scripted vignettes that illustrate key points. It is designed so that it can be used both for individual study as well as in a group learning setting...
Favorite
2010
This document is intended to raise awareness about TB/HIV research priorities (i.e. areas that require urgent funding and scientific interest), help coordinate advocacy efforts, and encourage research funding. The aim is to increase the implementation of high-quality, integrated TB/HIV interventions in resource-limited settings...
Favorite
International Agencies
Policy Makers
2010
The purpose of this document is to highlight cases in which Advocacy, Communication and Social Mobilization (ACSM) interventions have contributed to a positive outcome of tuberculosis (TB) control activities directed to a range of audiences and settings. It is intended for on-the-ground stakeholders who are interested in successfully integrating ACSM strategies and activities into TB control programming, as well as for decision-makers who can provide greater political and financial support for ACSM activities at the national, sub-national and international level.
Favorite
International Agencies
Managers and Supervisors
Outreach Workers
2010
This document addresses a broad range of ethical issues arising in TB programmes, ranging from informed consent and isolation to health-care workers' rights and obligations, and clinical and epidemiological studies.
Favorite
International Agencies
2010
The case highlighted in this issue came from a state health department nurse who lived in the small town located on a large Great Plains Indian reservation where this case unfolded. It involved an extended family spanning 4 generations, all of whom lived in the same 3-bedroom house.
Favorite
Health Educators/Communicators
Managers and Supervisors
Medical and Nursing School Students
Outreach Workers
Social Service Providers
2010
The challenges of TB-HIV co-Infection are highlighted in this issue. Psychosocial aspects of HIV diagnosis and self-awareness are also discussed.
Favorite
Health Educators/Communicators
Managers and Supervisors
Medical and Nursing School Students
Outreach Workers
Social Service Providers
2010
The Global Drug Facility (GDF) is a mechanism to expand access to, and availability of, high-quality anti-TB drugs and diagnostics to support the Stop TB Strategy.
This document outlines progress that GDF has made to date, what still needs to be done and where high-level advocacy could help GDF to further scale up its activities.
Favorite
International Agencies
Policy Makers
2010
The guidelines show how people with HIV can be protected from tuberculosis with regular, low-cost preventive medication. The guidelines present a set of recommendations that will help reduce TB disease in people living with HIV, their families and communities through a combination of screening for TB and provision of IPT.
Favorite
International Agencies
Policy Makers
2010
Drs. Jacques Grosset and Timothy Sterling will discuss the rationale for and potential new approaches to treatment of TB in HIV-infected individuals. Primary and secondary resistance of TB medications and the role of therapeutic drug monitoring for HIV-infected patients will be explored. The application of research to clinical practice will be highlighted.
Favorite
2010
The Checklist is designed to provide CHWs, supervisors, and program managers (from NTPs, NGOs, CBOs, and others) with very practical ways to properly implement TB IC and to minimize risk of transmission within community residential settings, including families and households.
Favorite
Infection Control and Occupational Health Workers
2010
This fact sheet provides basic information on the TB skin test.
Favorite
Persons With LTBI
2010
How to give a sample for testing for pulmonary tuberculosis. Most diagnostic tests for TB examine sputum coughed from the lungs. The lack of access to TB diagnosis is a major barrier to controlling TB which kills nearly 2 million people every year. New sensitive tests that are affordable and that can be used in a low tech environment are urgently needed.
Favorite
Persons With LTBI
2010
This hospital discharge approval request form is required in New York City as New York City Health Code mandates health care providers to obtain approval
from the New York City Department of Health & Mental Hygiene (DOHMH) before discharging infectious TB patients from the hospital.
Favorite
2010
The New York City Health Code requires all health care providers to submit a written TB Treatment Plan to the New York City Department of Health & Mental
Hygiene (DOHMH) within one month of starting treatment for newly diagnosed TB patients.
Favorite
2010
This report describes a study that determined whether differences in national trends in tuberculosis (TB) incidence are attributable to the variable success of control programs or to biological, social, and economic factors. Trends in case notifications were used as a measure of trends in incidence in 135 countries from 1997-2006, and regression analysis was used to explore the associations between these trends and 32 measures covering aspects of development, the economy, the population, behavioral and biological risk factors, health services, and TB control...
Favorite
2009
This report on the uses of nucleic acid amplification (NAA) tests for diagnosis of TB is based on contributions of an expert panel of consultants convened by the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL). The report presents the background for the study; general considerations, such as optimum patient care and public health, the value of NAA testing for clinicians and TB control officials, limitations of the tests, costs and funding issues, and turnaround time; research needs; available information on molecular drug susceptibility tests; the general recommendations of the panel; the communication plan for the new recommendations; and recommendations to the Advisory Council for the Elimination of TB (ACET), CDC, and the Division of TB Elimination (DTBE)...
Favorite
2009
This report presents results from an expert panel convened by CDC to examine the current status of rapid drug-resistance (DR) testing in the United States; to research published evidence and current guidelines; and to provide guidance and make recommendations to CDC for developing a system to provide access to rapid drug-susceptibility testing to all TB control programs in the United States...
Favorite
2009
This report provides World Health Organization (WHO) member states with guidance on preventing TB transmission in healthcare facilities, congregate settings, and households. It focuses on what to do and how to prioritize TB infection control at national levels and includes recommendations for national managerial activities...
Favorite
2009
This report describes the investigation by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), which initially identified five confirmed cases of multidrug-resistant tuberculosis (MDR TB) in two distinct clusters, characterized by two distinct geographic locations, genotypes, and drug-susceptibility patterns in the Federated States of Micronesia...
Favorite
2009
